Showing results (81-90 of 738) with videos related to
Sort By:
Pageof 74
Circulation|December 17, 2003
Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritisNaveed Sattar, David W McCarey, Hilary Capell, et al.Nature Reviews. Rheumatology|June 19, 2013
Changes in lipid levels with inflammation and therapy in RA: a maturing paradigmJamie Robertson, Mike J Peters, Iain B McInnes, et al.Nature Reviews. Rheumatology|January 26, 2017
Inflammatory mechanisms in tendinopathy - towards translationNeal L Millar, George A C Murrell, Iain B McInnesSeminars in Cell & Developmental Biology|August 14, 2016
Wounds that heal and wounds that don't - The role of the IL-33/ST2 pathway in tissue repair and tumorigenesisNeal L Millar, Charlotte O'Donnell, Iain B McInnes, et al.Rheumatology (Oxford, England)|July 18, 2013
Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritisJagtar Singh Nijjar, Alistair Tindell, Iain B McInnes, et al.Rheumatology (Oxford, England)|January 31, 2013
Alarmins in tendinopathy: unravelling new mechanisms in a common diseaseNeal L Millar, George A C Murrell, Iain B McInnesClinical Immunology (Orlando, Fla.)|April 2, 2020
Comorbidities associated with psoriatic arthritis: Review and updateLourdes M Perez-Chada, Joseph F MerolaJournal of the American Academy of Dermatology|February 26, 2018
Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasisBenjamin Lockshin, Yevgeniy Balagula, Joseph F MerolaAmerican Journal of Clinical Dermatology|April 10, 2015
Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologistsAmrita Goyal, Kavita Goyal, Joseph F MerolaNature Medicine|October 6, 2025
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trialIain B McInnes, Laura C Coates, Philip J Mease, et al.Pageof 74